Introduction
Methods
Case Reports
Case 1
Case 2
Results
Case report | Case report | Case 37-1976 [23] | Weingard [24] | Cohén [25] | Marterre [26] | Catalano [27] | Shah [28] | Sousa [29] | Trésallet [30] | |
---|---|---|---|---|---|---|---|---|---|---|
Age (years) | 63 | 52 | 4 weeks | 38 | 33 | 8 | 58 | 68 | 21 | 57 |
Underlying disease | AML | AML | AML | ALL | AML | AML | AML | AML | Aplastic anemia | Lymphoma |
Documentation | Histology + culture | Histology + culture | Histology + culture | Histology + culture | Histology + culture | Histology + culture | Histology + culture | Histology + culture | Histology + culture | Histology + culture |
Previous infection | Bacteremia | Bacteremia | Bacteremia | Bacteremia | Fever of unknown origin | Bacteremia | Fever of unknown origin | Suspected line infection | Fever of unknown origin | Fever of unknown origin |
Microorganisms |
Proteus vulgaris
|
Pseudomonas aeruginosa
|
Staphylococcus aureus
|
Klebsiella oxytoca; Enterococcus faecatis
| — |
Pseudomonas aeruginosa
| — | — | — | — |
Chemotherapy | Cytarabine, idarubicin | Cytarabine, idarubicin | Cytarabine, daunorubicin | Cytarabine, adriamicin | Cytarabine, daunorubicin | Vincristin | Cytarabine, daunorubicin | Cytarabine, idarubicin | Cyclosporin A | Cytarabine, etoposide |
Days after chemotherapy | 13 | 14 | 8 (second cycle) | 19 (second cycle) | 24 | 23 | 15 | 11 | 28 | Not specified (induction) |
Neutropenia at diagnosis | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes | Yes | Yes |
Antifungal prophylaxis | No | No | No | Not specified | Not specified | Not specified | Yes | Not specified | Not specified | Not specified |
Number of previous antibiotics | 3 | 3 | 3 | 2 | 5 | 3 | Several | 4 | Several | 3 |
Antimicrobial agents | Ciprofloxacin, gentamicin, metronidazole | Meropenem, amikacin, teicoplanin | Carbenicillin, gentamicin, oxacillin | Ceftazidime, amikacin | Ceftazidime, amikacin | Ceftazidime, tobramycin, ticarcillin | Not specified | Cefepime, metronidazole, gentamicin, vancomycin | Not specified | Imipenem, gentamicin, metronidazole |
Prior exposure to amphotrericin B | No | Yes | No | No | Yes | No | No | No | No | No |
Clinical presentation | Relapsing fever, ileus, peritonitis | Relapsing fever, ileus, bloody diarrhea, peritonitis | Relapsing fever, peritonitis | Relapsing fever, ileus, bloody diarrhea, peritonitis | Relapsing fever, watery diarrhea, peritonitis | Relapsing fever, ileus, peritonitis | Relapsing fever, digestive hemorrhage, peritonitis | Persisting fever, peritonitis | Persisting fever, peritonitis | Persisting fever, peritonitis |
Serology | — | — | — | — | — | — | — | — | — | — |
Antigenemia | — | — | — | — | — | — | — | — | — | 6.2 ng/ml (ELISA) |
Secondary dissemination | Lung | No | Lung, liver | Lung | Lung, liver | No | Not specified | Not specified | Not specified | No |
No. of surgical interventions | 1 | 2 | 1 | 1 | 2 | 5 | 1 | 1 | 1 | 1 |
Days after chemotherapy | 12 | 13 | 8 | 19 | 24 | 23 | 15 | 14 | 28 | Not specified |
Bowel excision | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes | Yes |
Antifungal treatment | Amphotericin B | Amphotericin B | — | — | — | — | Not specified | Not specified | Not specified | Voriconazole |
Outcome at 28 days | Death | Survival | Death | Survival | Death | Survival | Death | Death | Death | Survival |
Organ distribution | |||||||
---|---|---|---|---|---|---|---|
Authors | N | Mortality | Lung | Disseminated | CNS | Digestive | Primary digestive |
Autopsy
| |||||||
Young et al. [12] | 98 | 100% | 92 (94%) | 34 (35%) | 13 (13%) | 21 (21%) | 3 (3%) |
Meyer et al. [13] | 93 | 100% | 90 (98%) | 23 (35%) | 9 (10%) | 9 (10%) | 1 (1%) |
Boon et al. [11] | 32 | 100% | 32 (100%) | 20 (63%) | 16 (50%) | 15 (53%) | 0 |
Vogeser et al. [18] | 27 | 100% | 23 (85%) | 16 (59%) | 12 (44%) | 7 (26%) | 1 (4%) |
Vogeser et al. [31] | 48 | 100% | 41 (85%) | 28 (58%) | 21 (44%) | 1 (2%) | 0 |
Hori et al. [56] | 107 | 100% | 105 (98%) | 52 (52%) | 22 (21%) | 12 (11%) | 0 |
Total | 405 | 100% | 383 (95%) | 176 (43%) | 93 (23%) | 67 (17%) | 5 (1%) |
Retrospectiva
| |||||||
Fisher et al. [14] | 91 | 88% | 83 (91%) | 20 (22%) | 13 (14%) | 5 (5%) | 1 (1%) |
Albelda et al. [15] | 26 | 62% | 26 (100%) | NS | NS | NS | NS |
Morrison et al. [5] | 93 | 62% | 87 (95%) | 43 (47%) | 21 (23%) | NS | 1 (1%) |
Horvath and | 69 | 52% | 49 (71%) | NS | NS | NS | NS |
Dummer [33] | |||||||
Janssen et al. [34] | 25 | 92% | 25 (100%) | 8 (32%) | 3 (12%) | 4 (28%) | 0 |
Caillot et al. [35] | 37 | 27% | 37 (100%) | 8 (22%) | 0 | 0 | 0 |
Kaiser et al. [36] | 35 | 97% | 33 (94%) | 8 (23%) | 1 (3%) | 0 | 0 |
Abbasi et al. [37] | 66 | 85% | 46 (70%) | 23 (35%) | 9 (14%) | 0 | 0 |
Lortholary et al. [38] | 31 | 45% | 28 (90%) | 7 (23%) | 4 (13%) | 0 | 0 |
Nosari et al. [39] | 61 | 48% | 56 (92%) | 20 (33%) | 5 (8%) | 0 | 0 |
Pagano et al. [19] | 391 | 51% | 332 (85%) | NS | 37 ( 9%) | 9 (2%) | 4 (1%) |
Total | 925 | 60% 555/925 | 802 (87%) | 137/438 (31%) | 92/829 (11%) | 18/737 (2%) | 6/829 (0.7%) |
Prospective
| |||||||
Ringden et al. [40] | 32 | 34% | 29 (91%) | NS | NS | 0 | NS |
Denning et al. [20] | 76 | 32% | 51 (67%) | NS | 8 (11%) | NS | 1 (1.3%) |
Stevens et al. [21] | 125 | 34% | 90 (72%) | 24 (19%) | 8 (6%) | 0 | 1 (0.8%) |
Denning et al. [22] | 123 | 64% | 106 (87%) | 33 (27%) | 10 (8%) | 0 | 1 (0.8%) |
Patterson et al. [41] | 595 | 51% | 330 (56%) | 148 (25%) | 34 (6%) | NS | NS |
Denning et al. [42] | 116 | 58% | 81 (70%) | 6 (5%) | 19 (16%) | 0 | 0 |
Bowden et al. [44] | 174 | 53% | 107 (62%) | NS | 12 (7%) | NS | NS |
Herbrecht et al. [43] | 277 | 35% | 240 (87%) | 15 (5%) | 10 (4%) | NS | NS |
Total | 1,518 | 47% | 1,034 (64%) | 226/1,236 (18%) | 101/1,486 (7%) | 0/396 (0%) | 3/440 (0.7%) |
716/1518 | |||||||
All studies
| 2,848 | 59% | 2,219 (78%) | 539/2,079 (26%) | 296/2,720 (11%) | 85/1,538 (5.5%) | 14/1,674 (0.8%) |
1676/2848 |